PMID- 15518777
OWN - NLM
STAT- MEDLINE
DCOM- 20050414
LR  - 20181201
IS  - 0041-1345 (Print)
IS  - 0041-1345 (Linking)
VI  - 36
IP  - 7
DP  - 2004 Sep
TI  - Impact of fluvastatin on hyperlipidemia after renal transplantation.
PG  - 2141-4
AB  - BACKGROUND: Renal transplant recipients are at increased risk of atherosclerotic 
      vascular disease with hyperlipidemia. Many recipients have preexisting 
      cardiovascular disease at the time of transplantation, and immunosuppressive 
      therapy may aggravate existing risk factors or promote development of new risk 
      factors, notably hyperlipidemia and hypertension. Fluvastatin is one of the 
      statins, an HMG-CoA reductase inhibitor, which has been shown to be effective in 
      lowering cholesterol levels. We treated hyperlipidemia after renal 
      transplantation with Fluvastatin for more than 6 months. We attempted to clarify 
      the efficacy of fluvastatin on hyperlipidemia in renal transplant recipients. 
      MATERIALS: Forty-five renal transplant recipients with hyperlipidemia were 
      enrolled in this study. The mean age was 44.2 years, with 23 men and 22 women. 
      Thirty-seven transplantations were from a living related donors and eight from 
      cadaveric donors. Thirty-three recipients were ABO-compatible, seven recipients 
      had minor mismatches, and five recipients were ABO-incompatible. The dose of 
      fluvastatin was 20 mg per day. Levels of total cholesterol (TC), triglyceride 
      (TG), HDL cholesterol (HDL-C), LDL cholesterol (LDL-C), serum creatinine (s-Cr), 
      ALT, ALP, uric acid (UA), hematocrit (Ht), CPK, and blood pressure were examined 
      in all recipients before treatment as well as 1, 3, and 6 months after 
      Fluvastatin administration. RESULTS: The mean levels of TC and TG were 
      significantly reduced from 256, to 224 and 215 mg/dL, and from 188 to 170 and 147 
      mg/dL at 1 and 6 months after treatment, respectively. The mean levels of HDL-C 
      were 72 mg/dL before treatment, 81 mg/dL at 1 month, and 80 mg/dL at 6 months 
      after treatment. The mean levels of LDL-C were 153 mg/dL before treatment, 145 
      mg/dL at 1 month, and 145 mg/dL at 6 months after treatment. Fluvastatin 
      significantly produced a reduction rate in TC of 16%, TG of 22%, and LDL-C of 5% 
      after 6 months of treatment, respectively. The mean levels of HDL-C of were 
      increased 10% after 6 months of treatment. The serum creatinine and CPK were not 
      significantly different. There were no clinically significant differences in 
      other factors. No significant adverse effects were observed. CONCLUSIONS: 
      Fluvastatin seemed to be safe and highly effective to control TC, TG, LDL-C, and 
      HDL-C in renal transplant recipients.
FAU - Tokumoto, T
AU  - Tokumoto T
AD  - Department of Urology, Kidney Center, Tokyo Women's Medical University, Tokyo, 
      Japan. tokumoto@kc.twmu.ac.jp
FAU - Tanabe, K
AU  - Tanabe K
FAU - Ishida, H
AU  - Ishida H
FAU - Shimmura, H
AU  - Shimmura H
FAU - Ishikawa, N
AU  - Ishikawa N
FAU - Goya, N
AU  - Goya N
FAU - Akiba, T
AU  - Akiba T
FAU - Toma, H
AU  - Toma H
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
RN  - 0 (Anticholesteremic Agents)
RN  - 0 (Cholesterol, HDL)
RN  - 0 (Cholesterol, LDL)
RN  - 0 (Fatty Acids, Monounsaturated)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Indoles)
RN  - 0 (Triglycerides)
RN  - 4L066368AS (Fluvastatin)
RN  - 97C5T2UQ7J (Cholesterol)
SB  - IM
MH  - Adult
MH  - Anticholesteremic Agents/adverse effects/*therapeutic use
MH  - Blood Pressure/drug effects
MH  - Cholesterol/blood
MH  - Cholesterol, HDL/blood
MH  - Cholesterol, LDL/blood
MH  - Fatty Acids, Monounsaturated/pharmacokinetics/*therapeutic use
MH  - Female
MH  - Fluvastatin
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacokinetics/*therapeutic use
MH  - Hyperlipidemias/*drug therapy/etiology
MH  - Indoles/pharmacokinetics/*therapeutic use
MH  - *Kidney Transplantation
MH  - Male
MH  - Middle Aged
MH  - Postoperative Complications/*drug therapy
MH  - Triglycerides/blood
EDAT- 2004/11/03 09:00
MHDA- 2005/04/15 09:00
CRDT- 2004/11/03 09:00
PHST- 2004/11/03 09:00 [pubmed]
PHST- 2005/04/15 09:00 [medline]
PHST- 2004/11/03 09:00 [entrez]
AID - S0041-1345(04)00708-0 [pii]
AID - 10.1016/j.transproceed.2004.06.027 [doi]
PST - ppublish
SO  - Transplant Proc. 2004 Sep;36(7):2141-4. doi: 10.1016/j.transproceed.2004.06.027.